Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies.
about
Amantadine and rimantadine for influenza A in children and the elderlyA systems biology approach to the effect of aging, immunosenescence and vaccine responseThe unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccinesBooster vaccination against tetanus and diphtheria: insufficient protection against diphtheria in young and elderly adultsImmune Responses to Influenza Virus and Its Correlation to Age and Inherited FactorsCell culture-based influenza vaccines: A necessary and indispensable investment for the futureAge affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitisDistinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination.Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza VaccineImmune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender.Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine.Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children.High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza.Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens.AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans.Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine.Immunobiology of influenza vaccinesB cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccinationImpact of the raising immunizations safely and effectively (RISE) program on healthcare worker influenza immunization rates in long term care settings.Human immunophenotyping via low-variance, low-bias, interpretive regression modeling of small, wide data sets: Application to aging and immune response to influenza vaccinationParadoxical aging in HIV: immune senescence of B Cells is most prominent in young age.Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults.Influenza vaccination for older adults.Understanding immunosenescence to improve responses to vaccinesDistinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccinesOnset of immune senescence defined by unbiased pyrosequencing of human immunoglobulin mRNA repertoires.Characterization of influenza vaccine immunogenicity using influenza antigen microarrays.B cell function and influenza vaccine responses in healthy aging and disease.The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects.Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence.Defective TFH Cell Function and Increased TFR Cells Contribute to Defective Antibody Production in AgingExploiting human memory B cell heterogeneity for improved vaccine efficacy.CpG Improves Influenza Vaccine Efficacy in Young Adult but Not Aged Mice.Pregnancy Does Not Attenuate the Antibody or Plasmablast Response to Inactivated Influenza VaccinePreexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses.Telomere Length as an Indicator of the Robustness of B- and T-Cell Response to Influenza in Older Adults.Systems vaccinology: Enabling rational vaccine design with systems biological approaches.Sex and Gender Impact Immune Responses to Vaccines Among the ElderlyA Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.The confounded effects of age and exposure history in response to influenza vaccination
P2860
Q24187883-5B3FD355-9CF3-4983-ACE8-EF4B908BD2E9Q26994749-49093F97-A024-4BCD-B603-248C98EBAA5AQ27025076-D11EDB82-F5AD-47F2-A393-19C7EA39D784Q27468775-C2A3B802-2AEB-4A8A-A4AC-F1D80548CACCQ28075495-A583EC98-8162-4352-8943-3FBC914A23B1Q28084739-BDB689F2-DED2-42B7-B24F-082CEF50C50FQ28730933-7FD68D06-E031-4E0F-B830-DC256710238EQ30368005-5147518E-C855-47C6-8B34-EEB5684E0525Q30376743-AE2EA4B3-9E08-4CA2-A382-7AFD61CD5145Q30411189-3B188B25-F877-4535-8A78-B93E245460F2Q30412266-BF2782DC-2DA1-4268-965C-22F8AEEE10A8Q30413677-DDB09A9D-01CA-42E5-B1F4-17CFD182E2E6Q30416598-7B463094-1139-4B9E-8008-B699C4FF8743Q30418486-2A57E070-C6C6-45AA-8896-84BC1CE6DDC3Q30421821-F2BEA5D6-E733-4895-A6A0-507829C823B5Q30422951-1D5909F1-32F7-407A-B5E5-B1E116D122FBQ30426771-F661028B-7316-4EE6-ACE6-E3B0D272A751Q30429248-1AC4F200-26C6-4DE5-8254-A156E9D92EF8Q30539685-BAEAF9E4-97B0-46AA-8C58-F88D396B044AQ31097356-0839FB49-82C0-4183-B975-BCF03B9BC2D1Q33657511-25751C07-48DB-41A8-8B92-832466C21F29Q34218702-59CEAE9F-2392-4853-940A-44F299099787Q34247732-44F749D1-54FC-4173-928F-7D9C1B3B570CQ34281329-6EFE4BAF-6968-458E-9EC2-32E53F3BED7FQ34354440-888696AF-B42C-498A-91EC-BA92CAF5FABDQ34505044-C3EDD71B-56B6-4B1F-96C1-78BC170A680EQ34755553-4DCEB11A-6CAF-4A59-93D9-928CECDFD8FAQ35090929-69082A92-B3F3-4184-8AEE-EED0C93895B1Q35225020-60B94B52-1AD6-491F-85C7-61B2FEAA94C5Q35797338-1A9CE05F-4B07-45F3-B59A-850B2A716F52Q35858488-9934FD50-CB7F-40E6-B687-0C175F78D495Q35928222-BF6F55C3-1A4F-4BAD-8B32-C11D176C24ECQ35943193-DA67E196-E0BC-4DA6-892A-482F57AD66CCQ35993484-C66EAF2E-40F3-4C66-8DC5-848977AB02E8Q36051992-A29E9DAD-0BEB-4B0C-A53D-C7818AA5C3B8Q36078756-5C54AEBD-1EA8-4190-B75B-55E1218CF6DCQ36090112-1F8E2333-7D1E-40A7-9E06-E2C874C511B9Q36240727-5E01EB12-540F-44E2-9B82-4C77E7949D82Q36363243-B2B38937-FB3F-4D0B-9BB5-71E173749B95Q36495901-065EB7EB-1C45-4F2C-896D-311AA56A1323
P2860
Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Limited efficacy of inactivate ...... f vaccine-specific antibodies.
@ast
Limited efficacy of inactivate ...... f vaccine-specific antibodies.
@en
type
label
Limited efficacy of inactivate ...... f vaccine-specific antibodies.
@ast
Limited efficacy of inactivate ...... f vaccine-specific antibodies.
@en
prefLabel
Limited efficacy of inactivate ...... f vaccine-specific antibodies.
@ast
Limited efficacy of inactivate ...... f vaccine-specific antibodies.
@en
P2093
P2860
P50
P356
P1476
Limited efficacy of inactivate ...... f vaccine-specific antibodies.
@en
P2093
Carlos F Narvaez
Cornelia L Dekker
David Furman
Kenneth Smith
Madhuri Nishtala
Mark M Davis
Meghan Sullivan
Nai-Ying Zheng
Patrick C Wilson
Sanae Sasaki
P2860
P304
P356
10.1172/JCI57834
P407
P577
2011-07-25T00:00:00Z